Today: 11 November 2025
Subscribe
Browse Tag

GLP-1

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (Nov 6, 2025): NVO steadies as White House GLP‑1 pricing deal lands; $10B Metsera bidding war heats up

Date: Thursday, November 6, 2025Ticker: NVO (NYSE) At a glance: price action and catalysts Novo Nordisk stock traded around $47.36 as of 17:52 UTC, after opening at $47.75 and moving between $46.91–$49.49 on heavy volume. The tape is being driven by two big headlines: (1) a White House pricing agreement that expands access to GLP‑1 drugs across Medicare/Medicaid and a new direct‑to‑consumer channel, and (2) a $10 billion bidding battle with Pfizer for obesity‑drug startup Metsera. What changed today 1) White House pricing deal lowers GLP‑1 costs and expands coverage The administration announced a deal with Novo Nordisk and Eli
6 November 2025
 ·  ·  ·  ·  · 
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers (HIMS) Stock Soars on Subscriber Surge and GLP-1 Deal Buzz – Nov 2025 Update

Current Stock Price (Nov 3, 2025) Hims & Hers Health’s stock (NYSE: HIMS) closed on Nov 3, 2025 at $44.39, down about 2.3% for the day stockanalysis.com. This modest dip came amid a broader mixed market and ahead of the company’s earnings release after the bell. However, immediately following its Q3 earnings report that evening, HIMS shares jumped roughly 6% in after-hours trading, climbing to around $46.70 investing.com. The post-market pop was driven by upbeat revenue and subscriber numbers (more on that below), signaling renewed investor optimism. Even after recent volatility, HIMS stock has had a stellar year. At ~$44–$47,
4 November 2025
 ·  ·  ·  ·  · 
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net income simplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027 tipranks.com, and free cash flow turning positive in 2025 simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertainty simplywall.st. Key
3 November 2025
 ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

LLY Stock Snapshot and Recent Moves Eli Lilly’s stock (NYSE: LLY) has been on a tear this year, driven by blockbuster drug sales and upbeat guidance. As of Oct. 29, 2025, LLY traded near $813.53 investing.com. After hitting highs in the mid-$850s in early October, the shares have pulled back modestly (closing about 2% lower in the past week). Trading volume and technical indicators suggest a consolidation phase after the recent rally intellectia.ai intellectia.ai. Over the past 12 months LLY has significantly outperformed the broader market, in large part thanks to its GLP-1 diabetes/obesity franchise. Wall Street now assigns it a
30 October 2025
 ·  ·  ·  ·  · 
Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

GLP-1 Receptor Agonists and Neurodegenerative Diseases in 2025 GLP-1 receptor agonists like semaglutide (Ozempic®) are typically given via a weekly injection pen. Originally developed for diabetes and obesity, these drugs are now being studied for their effects on the brain. From Diabetes to Dementia: Why GLP-1 Drugs Are Being Tested for Brain Diseases Just a few years ago, GLP-1 receptor agonists were known mainly as diabetes and weight-loss medications. GLP-1 (glucagon-like peptide-1) is a natural hormone that helps regulate blood sugar and appetite. Drugs like Ozempic (semaglutide) and Victoza (liraglutide) mimic this hormone, improving insulin release and promoting a feeling
10 September 2025
 ·  ·  ·  ·  · 
Go toTop